Use of deferasirox in preparation of medicine for treating postmenopausal osteoporosis diseases

Abstract

The invention mainly relates to use of deferasirox, and in particular relates to use of deferasirox in preparation of a medicine for treating postmenopausal osteoporosis diseases. Deferasirox is used as the first oral iron chelating agent; compared with the traditional subcutaneous injection iron chelating agent, the deferasirox is low in toxicity, high in safety, convenient to administrate and good in compliance; and loss of postmenopausal bone mass can be obviously reduced.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the use of defesirox, in particular to the use of defesirox in the preparation of medicines for treating postmenopausal osteoporosis. Background technique [0002] Deferasirox (DFR), also known as deferasirox, its chemical name is 4-[3,5-bis-(2-hydroxyphenyl)-1H-[1,2,4]-tri Azol-1-yl] benzoic acid, molecular formula is C21H15N3O4, molecular weight 373.36, and its chemical structural formula is as follows: [0003] [0004] Desferezole is an iron chelator with three protruding ligands that bind iron with high affinity in a 2:1 ratio. The half-life of defezirox in the body is about 8 to 16 hours. Its low molecular weight and high lipophilicity determine that it can be administered orally and absorbed through the intestinal tract, and then enter the cells to chelate iron, metabolize through the liver, and secrete through the bile excreted in feces. As an essential trace eleme...

AI Technical Summary

Problems solved by technology

However, when the iron ions in the blood exceed the binding capacity of transferrin, free iron that is not bound by transferrin will be formed, resulting in iron overload

Images